ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO253

Magnesium Supplementation Reduces Vascular Calcification by Activating Calcium-Sensing Receptor (CaSR) in Vascular Smooth Muscle Cells

Session Information

  • Top Trainee Posters - 4
    October 26, 2024 | Location: Exhibit Hall, Convention Center
    Abstract Time: 12:00 PM - 01:00 PM

Category: Bone and Mineral Metabolism

  • 501 Bone and Mineral Metabolism: Basic

Authors

  • Gao, Qi, University of California San Francisco, San Francisco, California, United States
  • Cil, Onur, University of California San Francisco, San Francisco, California, United States
Background

Pathological deposition of calcium-phosphate in the arterial wall leads to vascular calcification, which is an important risk factor for cardiovascular mortality in CKD patients. Higher dietary Mg2+ intake was shown to reduce vascular calcification and cardiovascular mortality in clinical studies, however the mechanisms of Mg2+ effect remain unclear. Extracellular Ca2+-sensing receptor (CaSR) is a protein expressed in many tissues including vascular smooth muscle cells (VSMC). Although Ca2+ is considered as its main physiological agonist, we recently showed that Mg2+ (an often neglected CaSR agonist) is a more potent CaSR activator in certain tissues such as gut and lung.

Methods

We studied the roles of CaSR in therapeutic effects of Mg2+ in cell and mouse models of vascular calcification.

Results

In both mouse and human primary aortic smooth muscle cells, calcium-phosphate treatment (3 mM Ca2+, 2.5 mM PO43- for 7 days) resulted in marked calcification. Increasing Mg2+ in culture media concentration-dependently reduced calcification by up to 90% at 1 mM. The protective effects of Mg2+ were essentially abolished by CaSR inhibitor NPS-2143. Mg2+ concentration had minimal effects on calcification in primary cells derived from VSMC-specific CaSR knockout mice (SM22-Cre; Casr-flox), confirming key roles of CaSR in its efficacy. CaSR activation assays showed that Mg2+ is 2-5 fold more potent CaSR agonist than Ca2+ in human and mouse primary VSMC. In high dose vitamin D-induced vascular calcification model, mice fed with low (0.02%) Mg2+ diet had severe aortic calcification which was reduced by 32% and 66% in mice fed with normal (0.2%) and high (0.5%) Mg2+ diets, respectively. Aortic CaSR protein expression was found to be reduced by 85% and 60% in mice fed with low and normal Mg2+ diets, respectively, compared to controls. Co-staining showed that CaSR expression was primarily reduced in calcified areas. High Mg2+ diet resulted in largely preserved aortic CaSR expression in mice.

Conclusion

These results collectively suggest that Mg2+ is the key CaSR agonist in VSMC for prevention of vascular calcification. Mg2+ deficiency results in reduced CaSR activity and expression, which can be restored by its supplementation. Mg2+ supplementation can potentially be used as a simple, safe and effective treatment for preventing vascular calcification in CKD.

Funding

  • NIDDK Support